IDEAYA Biosciences, Inc. (IDYA) Q3 2025 10-Q Quarterly Report
IDEAYA Biosciences, Inc. (IDYA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
IDEAYA Biosciences, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • No newly added risk factors this quarter; critical accounting policies unchanged from 10-K filed February 18, 2025
- • Operating cash flows improved to positive $19.4M vs negative $125.9M in prior year driven by upfront Servier payment
- • Regulatory risk from Servier License Agreement obligations impacting operating cash inflows by $2.2M contract liabilities
- • Market risk: significant fluctuations in marketable securities activity with $541.3M maturities vs $371.8M purchases in current period
- • Financial risk: reliance on equity financing from at-the-market offerings raising $24.9M, down from $379.9M prior year
IDEAYA Biosciences, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$208M
Net Income
$119M
▲ +330.1% YoY▲ +253.9% QoQ
Operating Margin
52.2%
Net Margin
57.4%
ROE
10.9%
Total Assets
$1.2B
EPS (Diluted)
$1.35
▲ +325.0% YoY▲ +255.2% QoQ
Operating Cash Flow
$142M
▲ +388.9% YoY▲ +327.6% QoQ
Source: XBRL data from IDEAYA Biosciences, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on IDEAYA Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.